SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (776)4/25/2002 9:19:14 AM
From: bauke j deinum  Respond to of 1833
 
Guess that Janssen's Propulsid is targeted.A 5HT3 drug somewhat related to the anti-emetics that SK&F and Glaxo developed and to compounds being developed for IBS because of the motor effects. 5HT3 acting drugs do indeed act on a "particular serotonin receptor".
Propulsid was withdrawn because of serious adverse events.
I believe it was the only drug aimed at a muscle effect as opposed to an anti-acid effect.